NCT06364072View on ClinicalTrials.gov

Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

May 27, 2024

Primary Completion Date

May 9, 2025

Study Completion Date

May 9, 2025

Conditions
Pain
Interventions
DRUG

CT001

Intranasal

Trial Locations (7)

Unknown

Hospital General Universitario Dr. Balmis, Alicante

Hospital Sant Joan de Deu, Barcelona

Universidad Autonoma de Madrid (UAM) - Hospital Universitario La Paz (HULP) -, Madrid

Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela

Birmingham Women's and Children's NHS Foundation Trust, Birmingham

Royal London Hospital, London

Sheffield Children's Hospital, Sheffield

Sponsors

Lead Sponsor

Cessatech A/S
All Listed Sponsors
lead

Cessatech A/S

INDUSTRY

NCT06364072 - Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients | Biotech Hunter | Biotech Hunter